The stock is now moving above its 20-Day Simple Moving Average of 24.96% with the 50-Day Simple Moving Average of 24.96 percent.
Allianz Asset Management AG raised its position in shares of Exelixis, Inc. Following the EPS trend, pool of analysts gave current quarter Per-Share Earnings estimates trends of $2.34 for the AET while maintaining high price target of 154 and average of 136.50, as declared by WSJ. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Exelixis by 78.3% in the third quarter. The company's shares closed yesterday at $23.09, close to its 52-week high of $23.49. Metropolitan Life Insurance Co. NY now owns 164,278 shares of the biotechnology company's stock worth $1,283,000 after buying an additional 6,115 shares during the period. Farallon Capital Management LLC bought a new stake in Exelixis during the second quarter valued at $38,386,000.
Brief Synopsis About Exelixis, Inc.
Exelixis, Inc. has a 12 month low of $3.55 and a 12 month high of $23.02. (NASDAQ:EXEL) jumped 6.45% to reach at $23.09 during previous trading session. Meanwhile, EVP, Scientific Strategy & CSO Lamb Peter sold 70,000 shares worth $1025500, through a transaction dated 2017-01-03. To take look on ration of tradable shares being shorted in market, float short ration was 6.06%, as compared to sentiment indicator; Short Ratio was 2.91.
A number of brokerages have weighed in on EXEL. The biotechnology company reported $0.12 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.01) by $0.13. Finally, William Blair restated an "outperform" rating on shares of Exelixis in a research note on Saturday, January 28th. They issued a "buy" rating and a $17.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, Exelixis has a consensus rating of "Buy" and a consensus target price of $15.60.
The latest Insider trade was made on 31 Jan 2017 where LAMB PETER Officer did a transaction type "Buy" in which 55000 shares were traded at a price of $7.18. The shares were sold at an average price of $16.73, for a total transaction of $368,060.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Exelixis, Inc.'s (EXEL ) stock price distance from twenty day simple moving average surged at 9.98% while its distance from fifty day simple moving average raised 24.96% along with 80.27% above distance from two hundred simple moving averages. The disclosure for this sale can be found here.
In terms of earnings per share, 5 analysts have a 0.00 EPS mean target for the quarter ending Mar-17, for the quarter ending Jun-17, 5 analysts have a 0.00 EPS mean target and for the quarter ending Jun-17 there are 7 estimates of 0.09 EPS.
The company continues to focus on the launch of Cabometyx in the U.S. Exelixis plans to file supplemental New Drug Application (sNDA) for cabozantinib as a treatment for previously-untreated patients with advanced RCC in the third quarter of 2017 based on the positive data from the Cabosun randomized phase II trial. The Company is engaged in developing small molecule therapies for the treatment of cancer.
Want to see what other hedge funds are holding EXEL?